scholarly journals Visceral leishmaniasis in an immunocompetent patient

2020 ◽  
Author(s):  
Domingos Sousa ◽  
Miguel Seruca ◽  
Ana Isabel Rodrigues ◽  
Mourão Carvalho ◽  
Sara Aleixo Duarte ◽  
...  
Keyword(s):  
Visceral Leishmaniasis ◽  
Amphotericin B ◽  
Liposomal Amphotericin ◽  
Immunocompetent Patient ◽  
Liposomal Amphotericin B ◽  
History Of

A 26-year-old patient was admitted with a 6-month history of fever,fatigue,and unintentional weight loss.Abdominal CT described an heterogeneous hepatosplenomegaly.Laboratory studies revealed leucopenia,anemia and elevated CRP.Bone marrow aspirate revealed amastigotes compatible with Leishmania spp.Was treated with liposomal amphotericin B with favourable outcome.Authors intend to raise awareness of VL in immunocompetentpatients.

scholarly journals Case Report: Post Kala-Azar Dermal Leishmaniasis with History of Visceral Leishmaniasis

2021 ◽  
Vol 8 (5) ◽  
pp. 69-72
Author(s):  
Pavankumar Narapaka ◽  
Kalpana Katikala
Keyword(s):  
Visceral Leishmaniasis ◽  
Amphotericin B ◽  
Liposomal Amphotericin ◽  
Liposomal Amphotericin B ◽  
First Line ◽  
Treatment Regimens ◽  
First Line Therapy ◽  
Kala Azar ◽  
History Of

The complication of visceral leishmaniasis is post-kala-azar dermal leishmaniasis (PKDL). PKDL typically occurs as a result of treatment failure or parasite resistance to treatment regimens, as well as poor patient follow-up. In the treatment of visceral leishmaniasis and post-kala-azar dermal leishmaniasis, Liposomal Amphotericin B is considering as first-line therapy. We're going to show you a case where Liposomal Amphotericin B was used to treat it. Keywords: visceral leishmaniasis, post-kala-azar dermal leishmaniasis, PKDL, kala-azar

Treatment of resistant visceral leishmaniasis with interferon gamma in combination with liposomal amphotericin B and allopurinol

2019 ◽  
Vol 72 ◽  
pp. 101934 ◽  
Author(s):  
Mahmoud Khodabandeh ◽  
Ali Rostami ◽  
Katayoun Borhani ◽  
H. Ray Gamble ◽  
Mohsen Mohammadi
Keyword(s):  
Visceral Leishmaniasis ◽  
Amphotericin B ◽  
Interferon Gamma ◽  
Liposomal Amphotericin ◽  
Liposomal Amphotericin B

Treatment of visceral leishmaniasis in children with liposomal amphotericin B

1997 ◽  
Vol 131 (2) ◽  
pp. 271-277 ◽  
Author(s):  
Lucio di Martino ◽  
Robert N. Davidson ◽  
Raffella Giacchino ◽  
Silvestro Scotti ◽  
Francesco Raimondi ◽  
...  
Keyword(s):  
Visceral Leishmaniasis ◽  
Amphotericin B ◽  
Liposomal Amphotericin ◽  
Liposomal Amphotericin B

Liposomal Amphotericin B for Visceral Leishmaniasis in a Kidney Allograft Patient

2002 ◽  
Vol 18 (4) ◽  
pp. 187-191 ◽  
Author(s):  
Marina Valente ◽  
Massimo Marroni ◽  
Claudio Sfara ◽  
Daniela Francisci ◽  
Lisa Malincarne ◽  
...  
Keyword(s):  
Renal Transplant ◽  
Visceral Leishmaniasis ◽  
Transplant Recipient ◽  
Renal Transplant Recipient ◽  
Amphotericin B ◽  
Liposomal Amphotericin ◽  
Liposomal Amphotericin B ◽  
Blood Monocytes ◽  
Lipid Complex ◽  
First Case

Objective To report a case of visceral leishmaniasis treated with liposomal amphotericin B (LAB) after probable failure with amphotericin B lipid complex (ABLC). Case Summary A 62-year-old white renal transplant recipient was admitted for pyrexia, hepato-splenomegaly, and pancytopenia. Leishmania amastigotes were detected from bone marrow aspirate and in circulating blood monocytes and neutrophils. The patient, who weighed 56 kg, received ABLC at a starting dose of 200 mg/d (3.6 mg/kg of body weight per day) for 13 days, achieving a total dose of 2,600 mg (46 mg/kg) without clinical improvement. The patient was switched to 100 mg/d (1.8 mg/kg) of LAB for 10 days, after which a dose of 250 mg (4.5 mg/kg) was repeated on days 17,24,31, and 38. Twenty-four hours after the first dose of LAB, the patient showed an excellent clinical response. On the following days, there was a progressive increase in hemoglobin concentration and leukocyte and platelet counts. Three months later, the patient was asymptomatic. Discussion Although treatment with ABLC appears to be effective for the treatment of Indian patients with visceral leishmaniasis, experience with immunocompromised patients is limited. This is the first case of a renal transplant recipient in which ABLC was used to treat visceral leishmaniasis without remarkable efficacy, but with infusion-related adverse effects perhaps due to the use of higher doses. Conclusions A randomized comparative trial is needed to compare LAB with ABLC in the treatment of visceral leishmaniasis in patients who have received kidney allografts.

Sign in / Sign up

Export Citation Format

Share Document